Evaluation of Treatments for Dry or Productive Cough

Exclusion Criteria

• •Hypersensitivity or history of allergy to any component of the investigational products,
• •Severe, poorly tolerated cough,
• •Complicated acute rhinitis (e.g., acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia),
• •Chronic or allergic rhinosinusitis,
• •Bacterial tonsillitis or pharyngitis,
• •Positive antigen test for influenza A/B or COVID-19 requiring etiological treatment per current guidelines (Appendix 5),
• •Concurrent use of antitussives, bronchodilators, inhaled corticosteroids, other pulmonary-targeted therapies, or medications known to induce cough (such as ACE inhibitors, ARBs, etc.), antibiotics, antivirals, or any other treatment deemed incompatible with the study by the investigator,
• •Recent ENT surgery (\<6 months),
• •Pulmonary disease (e.g., COPD, asthma),
• •Immunodeficiency (based on patient declaration),
• •Comorbidities or a health status judged incompatible with the trial by the investigator (e.g., Gastroesophageal Reflux Disease \[GERD\] or abnormal lung auscultation),
• •Pregnant or breastfeeding women,
• •Regular tobacco smoker (as judged by the investigator),
• •Current participation in another clinical trial, being in an exclusion period from a previous trial, or having received total compensation exceeding 6000 euros in the 12 months prior to study start,
• •Under legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial safeguard).